Enable AccessibilityEnable Accessibility

COVID-19 HCP Letter

March 16, 2020
Dear Health Care Professional, 
As you are aware, the COVID-19 outbreak continues to expand, with significant interventions by public health authorities and governments here in Canada and around the world. As a global pharmaceutical leader, our top priority during this outbreak is to do all we can to protect the health of our employees, those who work alongside them, their families and our communities, while making sure our medicines and services continue to reach patients who rely on them. 
With this in mind, we have requested that all our employees work from home. As such, we will not be visiting physician offices, clinics, or hospitals at this time, unless there is a critical need or request to do so. Our goal is to do our part to reduce the risk of exposure for our employees, and stakeholders, like yourself, during this time. 
I want to assure you that we are here to continue to support patients and health care professionals, but that we will do this virtually wherever possible with the tools we have available. While we must temporarily adapt to a new normal, our firm focus remains on ensuring our medicines and services continue to reach patients who rely on them and in turn, play our part in allowing health care providers to focus on helping patients who need them in the coming months. 
I would like to thank you for your understanding and support during these exceptional circumstances. Should you have any questions, please do not hesitate to reach out to your Takeda representative. 
Gamze Yüceland
General Manager